Argos Therapeutics Announces CEO Jeff Abbey Elected to NCBIO Board of Directors
DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today …